Company: NIVFW
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001213900-25-079717
Chunk: 238

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-22
Form: DRS
Chunk 238
---
,
which may be increased from time to time as determined by the Board or Committee of the Board, in an amount equal to 20% of the then outstanding
ordinary shares of the Company at the time of such increase. Shares may be made available from Shares held in treasury or authorized but
unissued shares of the Company not reserved for any other purpose. To date, no shares have been awarded under this Plan.

On April 1, 2025, the Company
entered into a new Securities Purchase Agreement (“2025 Securities Purchase Agreement”) with JAK, pursuant to which, amongst
other things: (i) the Company agreed to sell, at an initial closing, a senior convertible note in the aggregate original principal amount
of $3,200,000, convertible into Class A Ordinary Shares pursuant to its terms; and (ii) the Company may require JAK (or JAK may require
the Company, as applicable) to participate in the sale of one or more additional convertible notes (which aggregate original principal
amount for all additional convertible notes shall not exceed $25,600,000).

On April 2, 2025, the Company
consummated the fourth tranche of its debt financing under the terms of its existing Securities Purchase Agreement with the investor, At
the closing of the fourth tranche, the Company sold to the investor a senior convertible note in the principal amount of $2,000,000.
The Note bears an interest rate of 14.75% per annum and may be adjustable from time to time pursuant to its terms. The funding from
these arrangements with the investor is intended to be used to finance the establishment of a fertility clinic in Dubai.

Mr. Yip Eng Jeremy Foo, a
director of NewGenIvf Group Limited (the “Company”), has resigned from the Board of Directors of the Company, the Audit Committee
of the Company, and the Compensation Committee of the Company due to personal reasons, effective April 4, 2025. Mr. Foo’s resignation
did not result from any disagreement with the Board or the Company on any matter relating to the Company’s operations, policies
or practices.

Ms. Florianna Ann Chi Wan
Chan will be appointed as a director of the Company, effective April 15, 2025, to fill the vacancy on the Audit Committee and the Compensation
Committee created by Mr. Foo’s resignation. Ms Chan has over 20 years of experience in project management, real estate development,
and luxury hospitality,